Our results are consistent with several prior studies: (1) one suggesting that blocking IL-1β signaling reduced CIPN symptoms in rats who received paclitaxel [52]; (2) a correlational study in humans suggesting that a single IL-1β polymorphism is a risk factor for CIPN [53]; and (3) a case-control study in humans suggesting perturbed gene expression in neuroinflammatory pathways in breast cancer survivors with CIPN vs. those without CIPN [54]. Here, IL1B is linked to breast cancer.